Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy

被引：2
|
作者：
Shakiba, Yasmin [1 ,2 ]
Vorobyev, Pavel O. O. [2 ]
Mahmoud, Marah [2 ]
Hamad, Azzam [2 ]
Kochetkov, Dmitriy V. V. [2 ]
Yusubalieva, Gaukhar M. M. [2 ,3 ,4 ]
Baklaushev, Vladimir P. P. [2 ,3 ,4 ]
Chumakov, Peter M. M. [2 ]
Lipatova, Anastasia V. V. [2 ]
机构：
[1] Moscow Inst Phys & Technol, Dolgoprudnyi 141701, Moscow Region, Russia
[2] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia
[3] Fed Med Biol Agcy FMBA, Fed Res Clin Ctr Specialized Med Care & Med Techno, Moscow 115682, Russia
[4] Fed Ctr Brain Res & Neurotechnol FMBA Russia, Moscow 117513, Russia
来源：
BIOCHEMISTRY-MOSCOW | 2023年 / 88卷 / 06期
基金：
俄罗斯科学基金会;
关键词：
oncolytic virus; recombinant virus; immunosuppression; immunomodulation; cytokine; vaccinia virus; COLONY-STIMULATING FACTOR; IMMUNOGENIC CELL-DEATH; GM-CSF; TUMOR-REGRESSION; IMMUNE-RESPONSE; CTLA-4; BLOCKADE; DOUBLE GENES; T-CELLS; PROTEIN; INTERLEUKIN-10;
D O I：
10.1134/S000629792306010X
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae, a family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of the VV strains as well as considerable transgene capacity of the viral genome, make VV an excellent platform for creating recombinant oncolytic viruses for cancer therapy. Furthermore, various genetic modifications can increase tumor selectivity and therapeutic efficacy of VV by arming it with the immune-modulatory genes or proapoptotic molecules, boosting the host immune system, and increasing cross-priming recognition of the tumor cells by T-cells or NK cells. In this review, we summarized the data on bioengineering approaches to develop recombinant VV strains for enhanced cancer immunotherapy.
引用
收藏
页码：823 / 841
页数：19
相关论文
共 50 条
  • [21] Antitumor effect of oncolytic vaccinia virus in gastric cancer
    Kim, Jee Hung
    Kwon, Woo Sun
    Kim, Tae Soo
    Park, Kyu Hyun
    Ahn, Joong Bae
    Lee, Namhee
    Choi, Ji Won
    Chung, Hyun Cheol
    Rha, Sun Young
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [22] VACCINIA AFTER IMMUNOTHERAPY USING RECOMBINANT VACCINIA VIRUS IN AIDS PATIENTS - 2 CASES
    GUILLAUME, JC
    SAIAG, P
    WECHSLER, J
    LESCS, MC
    ROUJEAU, JC
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1992, 119 (11): : 861 - 863
  • [23] Potentiating Cancer Immunotherapy Using an Oncolytic Virus
    Bridle, Byram W.
    Stephenson, Kyle B.
    Boudreau, Jeanette E.
    Koshy, Sandeep
    Kazdhan, Natasha
    Pullenayegum, Eleanor
    Brunelliere, Jerome
    Bramson, Jonathan L.
    Lichty, Brian D.
    Wan, Yonghong
    MOLECULAR THERAPY, 2010, 18 (08) : 1430 - 1439
  • [24] Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
    Liu, Liqiong
    Li, Huiqun
    Xu, Qinggang
    Wu, Yan
    Chen, Dongfeng
    Yu, Feng
    OPEN MEDICINE, 2022, 17 (01): : 1084 - 1091
  • [25] Inducible Gene Expression in Tumors Colonized by Modified Oncolytic Vaccinia Virus Strains
    Stritzker, Jochen
    Huppertz, Sascha
    Zhang, Qian
    Geissinger, Ulrike
    Haertl, Barbara
    Gentschev, Ivaylo
    Szalay, Aladar A.
    JOURNAL OF VIROLOGY, 2014, 88 (19) : 11556 - 11567
  • [26] Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma
    Yurttas, Can
    Beil, Julia
    Berchtold, Susanne
    Smirnow, Irina
    Kloker, Linus D.
    Sipos, Bence
    Loeffler, Markus W.
    Koenigsrainer, Alfred
    Mihaljevic, Andre L.
    Lauer, Ulrich M.
    Thiel, Karolin
    CANCERS, 2024, 16 (02)
  • [27] RECOMBINANT MUC-1 VACCINIA VIRUS - A POTENTIAL VECTOR FOR IMMUNOTHERAPY OF BREAST-CANCER
    BALLOUL, JM
    ACRES, RB
    GEIST, M
    DOTT, K
    STEFANI, L
    SCHMITT, D
    DRILLIEN, R
    SPEHNER, D
    MCKENZIE, I
    XING, PX
    KIENY, MP
    CELLULAR AND MOLECULAR BIOLOGY, 1994, 40 : 49 - 59
  • [28] COMPARISON OF THE ONCOLYTIC ACTIVITY OF RECOMBINANT VACCINIA VIRUS STRAINS LIVP-RFP AND MVA-RFP AGAINST SOLID TUMORS
    Shakiba, Y.
    Naberezhnaya, E. R.
    Kochetkov, D., V
    Yusubalieva, G. M.
    Vorobyev, P. O.
    Chumakov, P. M.
    Baklaushev, V. P.
    Lipatova, A., V
    BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2023, (02): : 4 - 11
  • [29] Oncolytic vaccinia virus vaccine Promising in liver cancer patients
    Riedmann, Eva M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (04) : 722 - 722
  • [30] Pan-cancer-specific engineered oncolytic vaccinia virus
    Yoo, So Young
    CANCER RESEARCH, 2022, 82 (12)
12345